AP24534 - a novel multi-targeted kinase inhibitor ARIAD’s second oncology product candidate, AP24534, is an internally discovered novel oral multi-targeted kinase inhibitor that has broad potential applications in cancer, including various forms of leukemia, a blood-based cancer. In preclinical studies, AP24534 has demonstrated potent inhibition of the kinase targets associated with drug-resistant chronic myeloid leukemia and acute myeloid leukemia – two prevalent types of leukemia. AP24534 has also demonstrated inhibition of angiogenesis in multiple solid tumors.
Recent data showed that AP24534 demonstrated efficacy and oral dosing flexibility in animal models of chronic myeloid leukemia (CML), including forms of CML caused by clinically relevant variants of the target protein, Bcr-Abl. Specifically, AP24534 potently inhibited all mutant forms of Bcr-Abl including T315I, which is completely resistant to the currently available drugs
